Angie You Buys 26,597 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) Director Angie You bought 26,597 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was bought at an average price of $9.39 per share, with a total value of $249,745.83. Following the completion of the acquisition, the director now owns 26,597 shares of the company's stock, valued at $249,745.83. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Angie You also recently made the following trade(s):

• On Monday, June 23rd, Angie You bought 1,403 shares of Oric Pharmaceuticals stock. The stock was bought at an average price of $9.43 per share, with a total value of $13,230.29.

Oric Pharmaceuticals Trading Up 2.6%

Shares of NASDAQ:ORIC traded up $0.27 during trading on Thursday, hitting $10.50. 1,739,709 shares of the stock were exchanged, compared to its average volume of 793,134. The company has a fifty day moving average price of $7.05 and a two-hundred day moving average price of $7.70. The company has a market cap of $894.81 million, a PE ratio of -5.61 and a beta of 1.49. Oric Pharmaceuticals, Inc. has a 12-month low of $3.90 and a 12-month high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. Equities research analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ORIC shares. JPMorgan Chase & Co. lifted their price target on Oric Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Oppenheimer decreased their price target on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Wedbush reaffirmed an "outperform" rating and set a $20.00 price target on shares of Oric Pharmaceuticals in a report on Monday. Guggenheim reaffirmed a "buy" rating on shares of Oric Pharmaceuticals in a report on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Oric Pharmaceuticals in a report on Monday, May 5th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $19.17.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Invesco Ltd. lifted its stake in shares of Oric Pharmaceuticals by 8.5% during the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock worth $193,000 after purchasing an additional 1,876 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Oric Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock worth $109,000 after buying an additional 2,520 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after buying an additional 3,131 shares during the last quarter. Swiss National Bank increased its holdings in shares of Oric Pharmaceuticals by 5.4% during the 4th quarter. Swiss National Bank now owns 62,400 shares of the company's stock worth $504,000 after buying an additional 3,200 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Oric Pharmaceuticals by 4.6% during the 4th quarter. Rhumbline Advisers now owns 93,319 shares of the company's stock worth $753,000 after buying an additional 4,072 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company's stock.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.